Edwards Lifesciences vs Thermo Fisher Scientific
Side-by-side comparison of AI visibility scores, market position, and capabilities
Irvine CA structural heart devices (NYSE: EW) at $5.44B 2024 revenue; 60% TAVR global share, EVOQUE tricuspid +88% in Q4, Critical Care sold to BD for $4.2B, JenaValve acquisition expanding to aortic regurgitation.
About
Edwards Lifesciences Corporation is an Irvine, California-based structural heart disease and hemodynamic monitoring technology company — publicly traded on the New York Stock Exchange (NYSE: EW) as an S&P 500 Healthcare component — designing, developing, and manufacturing devices for heart valve replacement, transcatheter heart valve therapy, and cardiac critical care through approximately 15,800 employees in 100+ countries. In fiscal year 2024, Edwards reported total revenue of $5.44 billion (+8.6% year-over-year), driven by its dominant Transcatheter Aortic Valve Replacement (TAVR) franchise commanding approximately 60% global market share and 70%+ US market share. The Transcatheter Mitral and Tricuspid Therapies (TMTT) segment demonstrated exceptional growth, with Q4 TMTT revenue reaching $105 million (+88% year-over-year), as the EVOQUE tricuspid replacement system gained commercial momentum. In 2024, Edwards executed a major strategic transformation: divesting its Critical Care segment (hemodynamic monitoring) to Becton Dickinson for $4.2 billion — using the proceeds to fund two acquisitions: JenaValve Technology ($1.2B combined, expanding TAVR to high-risk patients with aortic regurgitation) and Endotronix. The company concentrates its entire focus on structural heart disease therapies.
Thermo Fisher (TMO) reported $42.9B revenue in FY2024, down 1% YoY. World's #1 life sciences company. Serves pharma, biotech, labs globally. ~100,000 employees. HQ: Waltham, MA.
About
Thermo Fisher Scientific Inc. is the world's largest life sciences company, providing analytical instruments, reagents, consumables, software, and services to researchers, healthcare organizations, and industrial companies. Headquartered in Waltham, Massachusetts, Thermo Fisher was formed through the 2006 merger of Thermo Electron and Fisher Scientific and has since grown aggressively through acquisitions. The company reported revenues of $42.9B in FY2024, slightly down year-over-year after exceptional COVID-related revenue in 2021–2022.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.